Depot Buprenorphine is a new long acting formulation of an existing opioid pharmacotherapy, buprenorphine.
There are two depot buprenorphine products at this time: Buvidal® and Sublocade®
  • Buvidal® is available on the Pharmaceutical Benefits Scheme (PBS) from 1 September 2019 under a s100 Opioid Dependence listing.
  • Sublocade® is in the process of gaining PBS approvals with the Australian Government Therapeutic Goods Administration (TGA).

Clinical Guidelines

New interim guidelines for depot buprenorphine were developed to provide a framework for clinical decision making by clinicians and consumers in a range of service settings involved in the delivery of treatment with long acting depot buprenorphine products.

For additional advice on selected topics not included in the above guidelines, please see the Depot buprenorphine clinical guideline addenda

The guidelines should be read in conjunction with the NSW Clinical Guidelines: Treatment of Opioid Dependence.

Restricted Access Period and Prescriber Eligibility Criteria

The TGA approved depot buprenorphine products with an initial restricted access period of a minimum of 6 months. The restriction is to ensure experienced OTP prescribers who work in well supported clinical contexts (hospitals and specialist rehabilitation settings) are delivering this treatment.
Eligibility is limited in the first six months to accredited prescribers who meet both criteria 1. and  2. below:
  1. Specialised skills:
    • ​Addiction Medicine specialists and Addiction Psychiatry specialists in any setting, or
    • ​VMOs, CMOs, Nurse Practitioners and Registrars working in public OTP clinics, or
    • ​Prescribers in private OTP clinics with at least five years continuous accreditation and at least 100 patients
  2. Providing services in appropriately supported settings – that is, public or private clinics with on-site dispensing that have sufficient clinical/ staffing resources to implement depot buprenorphine.
During the restricted access period the TGA requires intending eligible prescribers to review the depot buprenorphine educational packages from the pharmaceutical companies. Please refer to the education package for Buvidall®​. The Sublocadel® education package will be available once the product listed on the PBS.
 

To register as a Depot Buprenorphine prescriber in the restricted access period please contact Pharmaceutical Regulatory Unit.

Consumer information

consumer information sheet on depot buprenorphine including frequently asked questions is available at NSW Government's Alcohol and Other Drugs information website Your Room.

Resources for clinicians

 
The Royal Australian College of General Practitioners (RACGP) has made available a free webinar: Introduction to Depot Buprenorphine in the Treatment of Opioid Dependent Patients. This webinar, presented by Professor Nick Lintzeris and Dr Hester Wilson, explains the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment (OAT) for opioid dependency.
 
The NSW Drug and Alcohol Specialist Advisory Service (DASAS) is a free 24/7 service for health professionals to seek advice on clinical diagnosis and management of patients with alcohol and other drug use. DASAS clinicians will provide advice on clinical issues related to depot buprenorphine.
Phone DASAS on:
  • Sydney metropolitan: (02) 9361 8006
  • Regional and rural NSW: 1800 023 687 (this free call number is not free from mobile phones, except Telstra mobiles)

​​
Page Updated: Tuesday 17 December 2019
Contact page owner: Centre for Population Health